Stereotaxis, Inc. completes Robocath acquisition to accelerate endovascular robotics expansion

Stereotaxis, Inc. completes Robocath acquisition to accelerate endovascular robotics expansion
Stereotaxis, Inc. completes Robocath deal

Stereotaxis, Inc. has announced the successful closing of its previously reported acquisition of Robocath, marking a significant step in the integration of advanced robotics into endovascular procedures.

The company stated that this move positions both firms to jointly pioneer the development of robotic technologies in vascular interventions. Stereotaxis, Inc. expects the collaboration to enhance its portfolio and drive future innovation in the field.

Stereotaxis, Inc. recently introduced its MAGiC system to improve precision and safety in complex arrhythmia care procedures for the heart, according to a prior announcement. The company also published a case study highlighting advancements in robotic electrophysiology led by Professor Sabine Ernst. These developments underscore Stereotaxis’s ongoing focus on expanding its robotics portfolio within cardiology and vascular care.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.